Business Context and Reporting Period
This Form 8-K filing by MEI Pharma, Inc. (trading symbol: MEIP) reports on the Annual Meeting of Stockholders held on December 5, 2019. The meeting covered the fiscal year ending June 30, 2020. Note: The request metadata lists "Lite Strategy, Inc.", but the filing text explicitly identifies the registrant as MEI Pharma, Inc.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. This document focuses exclusively on corporate governance and voting results.
Material Changes and Voting Results
Stockholders representing 53,167,909 shares (out of 73,654,927 outstanding) voted on three proposals:
- Proposal 1 (Election of Directors): Thomas C. Reynolds, M.D., Ph.D., and Christine A. White, M.D., were elected to three-year terms expiring in 2023. Both received over 36.6 million "For" votes.
- Proposal 2 (Advisory Vote on Executive Compensation): Approved with 36,354,500 "For" votes versus 335,629 "Against" votes.
- Proposal 3 (Ratification of Auditors): BDO USA, LLP was ratified as the independent registered public accounting firm with 52,268,398 "For" votes versus 854,231 "Against" votes.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, financial guidance, outlook, risk factors, or contingencies. It is a procedural report of the stockholder vote outcomes.
Key Facts for Investor Verification
- Verify the company name discrepancy between the request metadata ("Lite Strategy, Inc.") and the filing ("MEI Pharma, Inc.").
- Confirm the high number of broker non-votes (16,366,352) on director elections and executive compensation.
- Note that the newly elected directors serve terms expiring at the 2023 annual meeting.
- Confirm that BDO USA, LLP is the appointed auditor for the fiscal year ending June 30, 2020.